These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20659806)

  • 1. Mode of action of adjuvants: implications for vaccine safety and design.
    Mastelic B; Ahmed S; Egan WM; Del Giudice G; Golding H; Gust I; Neels P; Reed SG; Sheets RL; Siegrist CA; Lambert PH
    Biologicals; 2010 Sep; 38(5):594-601. PubMed ID: 20659806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive markers of safety and immunogenicity of adjuvanted vaccines.
    Mastelic B; Garçon N; Del Giudice G; Golding H; Gruber M; Neels P; Fritzell B
    Biologicals; 2013 Nov; 41(6):458-68. PubMed ID: 24071553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety.
    Mastelic B; Lewis DJ; Golding H; Gust I; Sheets R; Lambert PH
    Biologicals; 2013 Mar; 41(2):115-24. PubMed ID: 23194656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IABS international scientific workshop--Mode of Action of Adjuvants: implications for vaccine safety and design, April 29-30, 2010, Bethesda, MD, USA.
    Seemann S; Dodet B
    Vaccine; 2011 Apr; 29(17):3340. PubMed ID: 21335035
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).
    Hanquet G; Van Damme P; Brasseur D; De Cuyper X; Gregor S; Holmberg M; Martin R; Molnár Z; Pompa MG; Snacken R; van der Sande M; Van Ranst M; Wirtz A; Neels P
    Vaccine; 2011 Jan; 29(3):370-7. PubMed ID: 21075164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and effectiveness of the influenza vaccine: new data, new challenges].
    Trilla A
    Med Clin (Barc); 2013 Jul; 141(2):67-9. PubMed ID: 23768850
    [No Abstract]   [Full Text] [Related]  

  • 9. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of vaccine adjuvants: focus on autoimmunity.
    van der Laan JW; Gould S; Tanir JY;
    Vaccine; 2015 Mar; 33(13):1507-14. PubMed ID: 25659277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of adjuvanted pandemic influenza A (H1N1) 2009 vaccines.
    DeStefano F; Vellozzi C; Schonberger LB; Chen RT
    BMJ; 2011 Jul; 343():d4159. PubMed ID: 21750073
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice.
    Russell RF; McDonald JU; Lambert L; Tregoning JS
    J Virol; 2016 May; 90(9):4735-4744. PubMed ID: 26912628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of human-use adjuvants.
    Kenney RT; Edelman R
    Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current adjuvants and new perspectives in vaccine formulation.
    Montomoli E; Piccirella S; Khadang B; Mennitto E; Camerini R; De Rosa A
    Expert Rev Vaccines; 2011 Jul; 10(7):1053-61. PubMed ID: 21806399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.